Telix Pharmaceuticals (NASDAQ:TLX) Earns Outperform Rating from Wedbush

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “outperform” rating reissued by stock analysts at Wedbush in a note issued to investors on Wednesday, Benzinga reports. They currently have a $22.00 target price on the stock. Wedbush’s price target indicates a potential upside of 93.83% from the stock’s previous close.

Other research analysts have also recently issued research reports about the company. Weiss Ratings raised Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a research note on Tuesday, September 15th. Finally, Citigroup reaffirmed a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Telix Pharmaceuticals has an average rating of “Buy” and an average target price of $20.50.

Telix Pharmaceuticals Stock Up 0.7%

Shares of TLX opened at $11.35 on Wednesday. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.01 and a quick ratio of 1.85. Telix Pharmaceuticals has a one year low of $6.28 and a one year high of $13.11. The stock’s fifty day moving average is $11.32 and its 200-day moving average is $10.44.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. XY Capital Ltd boosted its position in Telix Pharmaceuticals by 468.0% during the 2nd quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock worth $822,000 after acquiring an additional 58,739 shares during the period. Hennion & Walsh Asset Management Inc. acquired a new stake in Telix Pharmaceuticals during the 2nd quarter worth about $1,731,000. Bank of America Corp DE boosted its position in Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after acquiring an additional 8,423 shares during the period. Lazard Asset Management LLC boosted its position in Telix Pharmaceuticals by 15.7% during the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after acquiring an additional 39,400 shares during the period. Finally, Private Advisor Group LLC raised its stake in shares of Telix Pharmaceuticals by 276.3% during the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after purchasing an additional 128,070 shares in the last quarter.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.